TABLE 1.
Baseline characteristics of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
| Characteristic | Patients (n=214) |
| Age years (n=211) | 58 (19–90) |
| Sex (n=214) | |
| Female | 111 (51.9) |
| ECOG performance status (n=205) | |
| 0–1 | 145 (70.7) |
| ≥2 | 60 (28.9) |
| Histology (n=207) | |
| Adenocarcinoma | 199 (96.1) |
| Undifferentiated carcinoma | 2 (1.0) |
| Other | 6 (2.9) |
| Number of metastatic sites (n=177) | |
| 0–2 | 117 (66.1) |
| ≥3 | 60 (33.9) |
| Metastatic localizations (n=210) | |
| Brain | 105 (50.0) |
| ALK test method (n=203) | |
| FISH only | 107 (52.7) |
| IHC only | 19 (9.4) |
| FISH and IHC | 74 (36.5) |
| Other | 3 (1.5) |
| Time from initial diagnosis to inclusion in TAU months (n=206) | 23.2 (1.7–192.8) |
| Prior medication regimens (including crizotinib) (n=213) | |
| 1 (crizotinib only) | 15 (7.0) |
| 2 | 97 (45.5) |
| >2 | 101 (47.4) |
| Median | 2 |
| Treatment line for crizotinib administration# (n=213) | |
| 1 | 27 (12.7) |
| 2 | 130 (61.0) |
| 3 | 35 (16.4) |
| >4 | 37 (17.4) |
| Crizotinib as last prior regimen# (n=213) | |
| Yes | 156 (73.2) |
| Duration of crizotinib treatment months (n=208) | 9.1 (0.1–52.0) |
| 25%–75% | 5.0–15.0 |
| Reason to stop crizotinib# (n=222) | |
| Disease progression | 203 (91.4) |
| Toxicity | 16 (7.2) |
| Other | 3 (1.4) |
Data are presented as n (%) or median (range) unless otherwise stated. ECOG: Eastern Cooperative Oncology Group; FISH: fluorescent in situ hybridisation; IHC: immunohistochemistry; TAU: temporary authorisation for use. #: crizotinib could be administered as more than one line/regimen for the same patient.